Tumor antigens structure and function

Cover of: Tumor antigens |

Published by Garland STPM Press in New York .

Written in

Read online


  • Tumor antigens.

Edition Notes

Includes bibliographies and index.

Book details

Statementedited by Harold Waters.
SeriesThe Handbook of cancer immunology ; v. 8
ContributionsWaters, Harold, 1942-
LC ClassificationsRC268.3 .H35 vol. 8, QR188.6 .H35 vol. 8
The Physical Object
Paginationviii, 418 p. :
Number of Pages418
ID Numbers
Open LibraryOL4092703M
ISBN 100824071123
LC Control Number80000775

Download Tumor antigens

Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines (Pages: ). This review summarizes studies on humoral immune responses against tumor-associated antigens (TAAs) with a focus on antibody frequencies and the potential diagnostic, prognostic, and etiologic.

Tumor Antigens Classification, Expression, and Immune Response. TAs can be divided into tumor-specific antigens (TSAs) that are unique antigens expressed by tumor cells and not by normal cells and tumor-associated antigens (TAAs), which are also expressed by normal cells although at lower levels than in tumor cells (see also Yang and Yang ).

Cellular & Molecular Immunology. ;2(5) Key Words:tumor, tumor antigen, new concept, anti-tumor immune response, immunotherapy. Introduction. The identification and molecular. For tumor antigens to be potential immunotherapeutic targets, the antigen must have no or highly restricted expression in normal tissues so that autoimmunity can be prevented.

Over the decades, several categories of antigens were found to fulfill this requirement, including uniquely mutated antigens (e.g. p53), viral antigens (e.g. human Cited by: Tumor antigen screening, and an understanding of the internalization characteristics and function of targeted antigen, will allow the optimal selection of mAbs for targeting.

The range of tumor antigens recognized by mAbs and the expanding therapeutic strategies that can be employed will form the basis of continuing clinical research. Antigens have been identified in most of the human cancers, including Burkitt lymphoma, neuroblastoma, melanoma, osteosarcoma, renal cell carcinoma, breast cancer, prostate cancer, lung carcinoma, and colon cancer.

A key role of the immune system is detection of these antigens to permit subsequent targeting for eradication. Antigens are classified as exogenous (entering from outside) endogenous (generated within cells), an autoantigen, a tumor antigen, or a native antigen.

Antigenic specificity is the ability of host cells to recognize an antigen by its unique molecular structure, such as the relationship between antigen epitopes and antibody paratopes.

Antigens are bits of protein on a cell’s surface. Tumor cells that mutate create malformed proteins called neoantigens. They act like a red flag to the immune system, telling it something is awry.

If the immune system sees the red flag, it sends T-cells to hunt down and attack the tumor. Tumor antigens are the basis of most cancer vaccine strategies and other types of specific cancer immunotherapy. They are targeted by application of various approaches, and using the peptides containing the epitope(s) of a tumor antigen benefits form an standard and easy method to evoke anticancer immunity.

Tumor Antigens - Holland-Frei Cancer Medicine - NCBI Bookshelf. The term “tumor antigen” has been given a new and much more precise definition as a result of important developments in immunology over the last decade, particularly in the area of antigen presentation and antigen recognition.

For something to be a tumor antigen, it must be recognized by specific immune effector. Purchase Vaccines for Cancer Immunotherapy - 1st Edition. Print Book & E-Book. ISBN  DOI link for Tumor Antigens Recognized by T Cells and Antibodies. Tumor Antigens Recognized by T Cells and Antibodies book.

Edited By Hans J Stauss, Yutaka Kawakami, Giorgio Parmiani. Edition 1st Edition. First Published eBook Cited by: 6. Tumor antigen is an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy.

Missing: book. Understanding tumor-infiltrating T cell recognition of shared tumor antigens is important for understanding cancer immune recognition and escape, and Tumor antigens book reveal novel targets for therapy.

Methods: We have established a novel approach for discovering shared tumor antigens in human lung cancer. This approach involves identifying candidate T cell receptor (TCR) alpha/beta. The papers explore progress in the field of clinical tumor immunology and cover topics ranging from general mechanisms in tumor immunity to tumor antigens and immunotherapy.

A classification of. The renewed interest in searching for tumor antigens likely to induce clinically significant responses is due to observations that melanoma and lung cancer that patients on checkpoint blockade immunotherapy respond better if their tumors have a large number of mutations identified by exome sequencing.

The hypothesis that is becoming popular is that the more mutations the tumor has, the more “foreign” antigens are seen on that tumor. Transplantation Antigens Transplantation Antigens by Barry Kahan. Download it Transplantation Antigens books also available in PDF, EPUB, and Mobi Format for read it on your Kindle device, PC, phones or lantation Antigens of the Human Fetus, Trophoblast, and Spennatozoa H.

SEIGLER AND R. METZGAR I. Transplantation Antigens on Cells of the. Tumor Antigens Recognized by T Cells and Antibodies provides a comprehensive overview of the molecular nature of tumor antigens that can be recognized by antibodies, helper T lymphocytes and cytotoxic T lymphocytes.

Novel strategies to enhance ineffective immunity against such antigens provide the basis for improved immunotherapy protocols for patient treatment. In the case of TIL, T cells recognizing a number of tumor-associated antigens (e.g., gp, MART-1, and HPV) and, more recently, oncogenes (e.g., mutated k-ras and p53) have been used to validate such antigens as potential tumor rejection antigens and to provide a population of T cells whose TCR can be sequenced and translated for engineered.

Cancer antigen (CA) corresponds to a carbohydrate structure, sialyl-Lewis a (SLe a), which is overexpressed on cancer cell surface as a glycolipid and/or as an O-linked glycoprotein. CA was first characterised by NS mAb [ ] and has been found primarily in pancreatic and biliary tract cancers [ ].

The binding of a CAR to the tumor antigen delivers a potent activating signal that triggers NK cell cytotoxicity, which results in the elimination of cancer cells. Several recent studies have documented a success using NK cells engineered to express activating chimeric antigen receptors (CARs) specific to tumor antigens [ 73 ].

The purpose of the National Cancer Institute pilot project to prioritize cancer antigens was to develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on predefined and preweighted objective criteria.

An additional aim was for the National Cancer Institute to test a new approach for prioritizing translational research opportunities based on an analytic hierarchy. Tumor Antigens.

Many tumor cells produce antigens, which may be released in the bloodstream or remain on the cell surface. Any molecule capable of being recognized by the immune system is considered an antigen.

Antigens have been identified in most of the human cancers, including Burkitt lymphoma, neuroblastoma, melanoma, osteosarcoma, renal cell carcinoma, breast cancer, prostate cancer, lung carcinoma, and colon g: book.

Book Description. Recent progress in fundamental tumor immunology has led to immunotherapy trials in patients with solid tumors and hematological malignancies.

In the past, immunotherapy approaches were primarily based on enhancement of tumor immunity with cytokines and adjuvant therapy, without knowledge of relevant tumor antigens.

The. Tumor-associated antigens (TAA) are tumor-specific proteins that can be recognized by immune effector cells of the host. To date, a variety of TAA are known. There are 2 main types of tumor antigens: Tumor-specific transplantation antigens (TSTA) which are unique to tumor cells and not expressed on normal cells.

They are responsible for rejection of the tumor. Tumor associated transplantation antigens (TATA) that are expressed by tumor cells and normal cells. NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine.

Tumour Antigens Recognized by Antibodies Andrew M Scott,Ludwig Institute for Cancer Research, Melbourne, Australia Christoph Renner,Saarland University, Homberg/Saar, Germany Antigens are frequently overexpressed on tumours, and the recognition of these antigens by antibodies can be used for tumour characterization, and for potential diagnostic and.

Tumor-associated antigens in PCa can be proteins that are present on prostate cells and on their malignant counterparts. Examples are prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and the cancer/testis antigens (CTAs).

In a steady state, these antigens are not provoking strong immune responses. tumour antigens; antigen specific T cell response; Spontaneous immune responses against human tumours have been reported in different types of cancer, especially in melanoma and renal cell carcinoma, 1, 2 but also in other types of cancer, such as non-small cell lung cancer, bladder carcinoma, and breast cancer, indicating the specific interaction of the immune system with antigenic.

Tumor antigens could also potentially be used in the development of vaccines for specific types of cancers. Vaccines work by exposing the body to a controlled dose of an antigen, allowing the immune system to develop antibodies which will attack that antigen if it is detected in the future.

Tumor antigens could be used in the same way, teaching the body to attack and kills Missing: book. Tumor specific transplantation antigens on chemically-induced tumors • Chemically-induced tumors are different from virally-induced tumors in that they are extremely heterogeneous in their antigenic characteristics.

Thus, any two tumors induced by the same chemical, even in the same animal, rarely share common tumor specific antigens (Figure 2).Missing: book. TUMOR CELL TUMOR ANTIGENS SWATHI PRABHAKAR [] III Year, Biotech Anna university [BIT Campus] Trichy [email protected] 2.

Tumor antigen is an antigenic substance produced in tumor cells. i.e., it triggers an immune response in the host. These antigens are not membrane proteins but are derivatives of Missing: book.

A tumor marker is anything present in or produced by cancer cells or other cells of the body in response to cancer or certain benign (noncancerous) conditions that provides information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it.

Cancer antigen test Your doctor may order a CA test if you’re about to start treatment for ovarian cancer. The test will help them determine how active your tumor is now and after your Missing: book. Get this from a library. Tumor antigens recognized by T cells and antibodies.

[Hans J Stauss; Yutaka Kawakami; Giorgio Parmiani;] -- Providing a comprehensive overview of the molecular nature of tumor antigens, this book provides invaluable information for all clinicians and researchers with an interest in cancer immunotherapy.

Tumor antigens targeted by spontaneous T cell responses of cancer patients Antigens produced by gene mutations. Mutated genes contribute greatly to the immunogenicity of human tumors. In cancer patients, about one half of the highly tumor-specific antigens recognized by spontaneous T cell responses are encoded by mutated genes, the other half being encoded by cancer-germline g: book.

ISBN: OCLC Number: Notes: Papers presented at a symposium held in Osaka, Dec., and sponsored by the Japanese Cancer Association. Tumor Antigen Targets for T Cell Therapies.

One key aspect of T cell therapy is to identify tumor antigen targets which can be recognized by T cell receptors (TCR) on cytotoxic T lymphocytes and induce malignant cell death. Selecting specific antigens within a patient’s tumor cell repertoire allows for highly personalized cancer g: book.

and later on chromosomal analysis. The third era () was discovery of onco developmental markers e.g. AFP, CEA. The fourth era started in with the development of monoclonal antibodies and their use to detect oncofetal antigens and antigens derived from tumor cell lines like carbohydrate antigens (CA, etc.).The detection of circulating tumor cells in blood () requires highly sensitive, specific, and reproducible methods.

During the last decade, immunocytochemistry (5, 6), reverse transcription-PCR (), flow cytometry (), and CellSearch and CellSpotter systems (14) have been assessed for the early detection of these rare circulating cells to predict tumor progression, survival in.Fig.

1. KU-CT-1 is a cancer testis antigen that is frequently expressed in pancreatic and endometrial cancers. A, expression of KU-CT-1 (TW3) in various cancer cell lines, cancer tissues, and normal testis evaluated by reverse transcription-PCR analysis.

Thirty cycles of PCR were done with total RNAs obtained from various cancer cell lines, cultured noncancer cells, and cancer and normal tissues.

14695 views Friday, November 13, 2020